Drugs / ACC-1898
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07252661 | Jan 2026 → Jun 2027 expected | gallbladder cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma +3 | AccSalus Biosciences, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACC-1898 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07252661 ↗ |
| Action | Inhibit | “ACC-1898 (also known as ST-1898) is a small-molecule inhibitor designed to block several RTK pathways simultaneously.” NCT07252661 ↗ |
| Modality | Small molecule | “ACC-1898 is an oral small-molecule tyrosine kinase inhibitor (TKI).” NCT07252661 ↗ |
| Route | Oral | “Administered once daily by mouth in continuous 21-day cycles.” NCT07252661 ↗ |